Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma
jRCT2080223264Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of durvalumab and tremelimumab (monotherapy and combination) and Clinical activity of durvalumab and tremelimumab (monotherapy and combination). Started Jul 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223264.